|
March 14, Sunday 4:30 PM to 6:00 PM
An ATHENA trial showed that after a 30-month follow up of more than 4,000 atrial fibrillation (AF) and atrial flutter patients, cardiovascular hospitalizations and death occurred 24 percent less in patients administered dronedarone than in those administered a placebo. A post-hoc analysis of the ATHENA trial also showed that those on the drug had a reduction in stroke.
While amiodarone has been on the U.S. market since the mid-1980s, dronedarone is a new-comer. How do physicians gauge the difference between drugs that have been around for decades with newer-generation therapies? In this session. Dr. Peter Smith from Marshfield, Wis., will present anti-arrhythmic case presentations and a panel of distinguished physicians in the EP field will discuss the ramifications.
An anti-arrhythmic drug used in the treatment of atrial fibrillation (AF), dronedarone (Multaq; Sanofi-aventis), has been approved in all 27 European member states by the European Commission.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Sanofi-Aventis’ atrial fibrillation drug Multaq (dronedarone–400mg tablets).
Sanofi-Aventis has made Multaq (dronedarone) 400 mg tablets available in pharmacies in the U.S. Multaq, an anti-arrhythmic drug, is indicated to reduce the risk of cardiovascular (CV) hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated CV risk factors, who are in sinus rhythm or who will be cardioverted.
Dronedarone had no adverse effect on mortality in atrial fibrillation (AF) patients with congestive heart failure (CHF) and/or a left ventricular ejection fraction less than 0.35; and patients had a lower incidence of primary outcome events when allocated to dronedarone therapy, according to the ATHENA late-breaking clinical trial presented May 15 at the 30th annual meeting of the Heart Rhythm Society (HRS) in Boston.
Multaq (dronedarone), in addition to standard therapy, significantly reduced the risk of first cardiovascular (CV) hospitalization or death by 24 percent in patients with atrial fibrillation or a recent history of these conditions, according to the ATHENA trial published today in the New England Journal of Medicine.
|
Asymptomatic atrial fibrillation (AF), compared with symptomatic patients, are more often older and at greater risk for thromboembolism and stroke, according to research presented by John Camm, MD, of the St. George’s University of London at the 15th annual Boston AF Symposium on Jan. 14.
A reduction in stroke was observed in patients with atrial fibrillation who were receiving usual care, which included antithrombotic therapy and heart rate control, and were randomized to dronedarone (Multaq, Sanofi-Aventis), according to a post-hoc analysis of the ATHENA trial, published Sept. 10 online in Circulation.
Health Canada has approved Sanofi Aventis’ Multaq (dronedarone, 400 mg tablets) for the treatment of patients with a history of or current atrial fibrillation to reduce their risk of hospitalization.
The FDA has approved Sanofi-aventis' Multaq (dronedarone) 400 mg tablets. Multaq is the first drug approved in the U.S. that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter, according to the firm.
The FDA's cardiology drug panel voted 10-3 this Wednesday to approve Sanofi-Aventis' Multaq (dronedarone) to treat patients with non-permanent atrial fibrillation (AF)--the first new treatment in 25 years.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).
A new hospital breaking ground usually isn’t breaking news. But the vision of patient care at one new facility, tentatively named Palomar Medical Center West (PMC West), is currently illegal under California state law.
There are cases presented to all physicians when we have to balance benefits of a particular treatment with concerns around safety for certain patients. In interventional cardiology, we see this dilemma with drug-eluting stents (DES). While this technology provides effective therapy for many patients with ischemia-inducing coronary lesions, there are certain patient groups that encounter problems for different reasons.